Leucovorin-induced Hypersensitivity Reaction in a Patient with Metastatic Colorectal Cancer Treated with Cetuximab Plus FOLFOX Chemotherapy: A Case Report
The Korean Journal of Gastroenterology · 2023
DOI: 10.4166/kjg.2023.114 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Korean Journal of Gastroenterology, 2023. Verfasst von Minna Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Rectal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
The FOLFOX regimen (combination of leucovorin, 5-fluorouracil, and oxaliplatin) is the first-line treatment for high-risk stage 2 and 3 colorectal cancer patients. While hypersensitivity reactions (HSRs) caused by oxaliplatin are commonly reported, HSRs due to leucovorin have been infrequently reported. This report aims to investigate the clinical presentation, diagnosis, and management of leucovorin induced HSRs. A 60-year-old female developed generalized edema, dyspnea, and facial redness during cetuximab plus FOLFOX chemotherapy administered for management of metastatic colorectal cancer. Because HSRs induced by oxaliplatin are commonly reported, we initially presumed an oxaliplatin-induced HSR. However, despite undergoing oxaliplatin desensitization, HSRs persisted, and they were still observed when leucovorin was administered without oxaliplatin. The patient was diagnosed with leucovorin-induced HSR and underwent leucovorin desensitization. However, the reactions recurred within 30 minutes of the initiating the desensitization. Considering unsuccessful leucovorin desensitization, leucovorin was excluded. The patient received cetuximab and oxaliplatin chemotherapy without leucovorin to date without any adverse effects. While leucovorin-induced HSRs are infrequently reported, they should still be regarded as potential adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
- Division of Allergy and Clinical Immunology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
ORCID-Profile: Jong Yoon Lee
Zitieren
APA
Kim, M., Kim, D. H., Lee, J. Y., Nam, Y. H., & Lee, J. H. (2023). Leucovorin-induced Hypersensitivity Reaction in a Patient with Metastatic Colorectal Cancer Treated with Cetuximab Plus FOLFOX Chemotherapy: A Case Report. The Korean Journal of Gastroenterology. https://doi.org/10.4166/kjg.2023.114
Vancouver
Kim M, Kim DH, Lee JY, Nam YH, Lee JH. Leucovorin-induced Hypersensitivity Reaction in a Patient with Metastatic Colorectal Cancer Treated with Cetuximab Plus FOLFOX Chemotherapy: A Case Report. The Korean Journal of Gastroenterology. 2023. doi:10.4166/kjg.2023.114
BibTeX
@article{Kim2023,
author = {Kim, Minna and Kim, Dong Hyun and Lee, Jong Yoon and Nam, Young-Hee and Lee, Jong Hoon},
title = {Leucovorin-induced Hypersensitivity Reaction in a Patient with Metastatic Colorectal Cancer Treated with Cetuximab Plus FOLFOX Chemotherapy: A Case Report},
journal = {The Korean Journal of Gastroenterology},
year = {2023},
doi = {10.4166/kjg.2023.114}
}
EUVIMED